Abeona Therapeutics Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

SHORT-TERM INVESTMENTS

SHORT-TERM INVESTMENTS

12 Months Ended

Dec. 31, 2024

Investments, Debt and Equity Securities [Abstract]

SHORT-TERM INVESTMENTS

NOTE 3 – SHORT-TERM INVESTMENTS

The following table provides a summary of the short-term investments (in thousands):

	December 31, 2024
	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Fair Value

Available-for-sale, short-term investments:
U.S. treasury securities	$	23,990		—		(22	)	$	23,968
U.S. federal agency securities		40,365		10		—			40,375
Certificates of deposit		10,000		20		—			10,020
Total available-for-sale, short-term investments	$	74,355		30		(22	)	$	74,363

	December 31, 2023
	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Fair Value

Available-for-sale, short-term investments:
U.S. treasury securities	$	8,406		—		(13	)	$	8,393
U.S. federal agency securities		29,413		—		(53	)		29,360
Total available-for-sale, short-term investments	$	37,819		—		(66	)	$	37,753

As of December 31, 2024, the available-for-sale securities classified as short-term investments mature in one year or less. The Company carries its available-for-sale securities at fair value in the consolidated balance sheets. Unrealized losses on available-for-sale securities as of December 31, 2024, were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. None of the short-term investments have been in a continuous unrealized loss position for more than 12 months. Accordingly, no other-than-temporary impairment was recorded for the year ended December 31, 2024.

There were no significant realized gains or losses recognized on the sale or maturity of available-for-sale investments during the years ended December 31, 2024 or 2023.